PSP94融合蛋白在大肠杆菌中的表达及其抗前列腺癌活性分析

在从成年人正常前列腺组织中获得人９４个氨基酸的前列腺分泌蛋白（ＰＳＰ９４）ｃＤＮＡ基础上,利用ＰＬ表达系统,实现了人ＰＳＰ９４成熟肽Ｎ－末端带有１９个列源氨基酸的融合蛋白在大肠杆菌中的表达。目的蛋白在细胞中主要以包涵体形式存在。表达量约占菌体总蛋白的３０％,分子量约为１６．５ｋＤ。表达产物在人前列腺癌细胞ＰＣ－３上活性分析表明,该融合蛋白能明显抑制前列腺癌细胞的生长。     

人PSP94全长cDNA的获得及PSP94-TNF~Δ融合蛋白的构建

利用ＲＴ－ＰＣＲ从人肥大前列腺组织钓取９４个氨基酸的人前列腺分泌蛋白（ＰＳＰ９４）全长ｃＤＮＡ,序列分析结果与文献报道的完全一致．将ＰＳＰ９４成熟肽与人ＴＮＦα衍生物（ＴＮＦΔ）通过Ｌｉｎｋｅｒ－ＳＡＰＧＴＰ在基因水平上融合成５′ＰＳＰ９４－ＴＮＦΔ,融合基因ＤＮＡ序列分析结果与设计的相符合．５′ＰＳＰ９４－ＴＮＦΔ在大肠杆菌中表达产物分子量约为３１ｋＤ,表达量约占菌体总蛋白量的３５％．以Ｌ９２９细胞和人前列腺癌细胞株ＰＣ－３为靶细胞进行细胞毒分析结果表明,５′ＰＳＰ９４－ＴＮＦΔ融合蛋白既具有ＴＮＦ的细胞毒活性,又具有对前列腺癌细胞ＰＣ－３的杀伤作用     

以融合蛋白形式在大肠杆菌中表达人MCP—1

将编码人单核细胞趋化蛋白－１（ＭＣＰ－１）的基因亚克隆到大肠杆菌表达载体ｐＥＸ３１Ａ中,在大肠杆菌中表达出ＭＳ２／ＭＣＰ－１融合蛋白,该表达产物约占菌体总蛋白的１５％左右,Ｗｅｓｔｅｒｎ ｂｌｏｔ检测表明,表达产物可与ＭＣＰ－１抗体特异反应,采用琼脂糖平板法进行活性测定表明,表达产物具有明显的单核细胞趋化活性,说明Ｎ端融合一段细菌蛋白对ＭＣＰ－１有无趋化活性可能没有影响。     

外源高表达PC-1蛋白N端43个氨基酸可加速人前列腺癌细胞系C4-2的生长

研究PC-1蛋白N端43个氨基酸表达对人前列腺癌细胞C4—2生长的影响。用DNA重组技术将含PC—1蛋白N端43个氨基酸的DNA序列正向克隆到真核表达载体pIRES2-EGFP中,采用脂质体法将重组质粒稳定转染进C4—2细胞中,RT—PCR分析外源序列的转录情况,固相ELISA法测定PC—1蛋白N端43个氨基酸的表达,MTT实验分析细胞的生长速度。结果获得了稳定转染PC—J基因N端43个氨基酸的前列腺癌细胞株,在该细胞株中外源PC—1蛋白N端43个氨基酸得到高表达,细胞生长速度较对照细胞加快了38％。结果表明外源PC—I基因N端43个氨基酸高表达可提高人前列腺癌细胞C4—2的生长速度,推论PC—J基因高表达可能在人前列腺癌的发展中起一定的促进作用。     

兔阑尾中一种新的21kD的钙结合蛋白的纯化与鉴定

纯化与鉴定了Ｂ淋巴细胞中一种新的分子量为２１ｋＤ的钙结合蛋白（ＣａＢＰ２１）。兔阑尾淋巴细胞匀浆经热变性,Ｐｈｅｎｙｌ－Ｓｅｐｈａｒｏｓｅ与ＤＥＡＥ－Ｓｅｐｈａｒｏｓｅ柱层析,自每１ｋｇ细胞沉积物中获得ＳＤＳ－ＰＡＧＥ均一的ＣａＢＰ２１５．３ｍｇ。ＨＣｌ水解后的酸性氨基酸（Ａｓｐ＋Ｇｌｕ）含量为２６％。如同大多数钙结合蛋白一样,Ｎ末端封闭阻止其进行Ｅｄｍａｎ降解。ＣａＢＰ２１中疏水性氨基酸（计Ｇｌｙ,不计Ｔｒｐ）约占４６％,碱性氨基酸１０％,酸性氨基酸与极性氨基酸约４４％。ＣａＢＰ２１有较高的Ｓｅｒ、Ｔｙｒ含量。肽谱分析等确证ＣａＢＰ２１为２个相同或相似亚基二聚体。以ＡｒｓｅｎａｚｏⅢ作Ｃａ２＋结合分析表明每分子ＣａＢＰ２１可结合４分子Ｃａ２＋,对Ｃａ２＋的结合常数约为１０－５ｍｏｌ／Ｌ。各种性质表明ＣａＢＰ２１是一种不同于其他已知钙结合蛋白的新钙结合蛋白。     

以融合蛋白形式在大肠杆菌中表达人MCP－1

将编码人单核细胞趋化蛋白－１（ＭＣＰ－１）的基因亚克隆到大肠杆菌表达载体ｐＥＸ３１Ａ中,在大肠杆菌中表达出ＭＳ２／ＭＣＰ－１融合蛋０白,该表达产物约占菌体总蛋白的１５％左右,Ｗｅｓｔｅｒｎｂｌｏｔ检测表明,表达产物可与ＭＣＰ－１抗体特异反应。采用琼脂糖平板法进行活性测定表明,表达产物具有明显的单核细胞趋化活性,说明Ｎ端融合一段细菌蛋白对ＭＣＰ－１有无趋化活性可能没有影响。     

水稻矮缩病毒最外层外壳蛋白基因（S2）cDNA克隆,序列分析及其在大？…

从水稻矮缩病毒（Ｒｉｃｅｄｗａｒｆｖｉｒｕｓ,ＲＤＶ）中国福建分离物中克隆分离了最外层外壳蛋白基因（Ｓ２）全长ｃＤＮＡ并对其进行序列分析,结果表明ＲＤＶＳ２ｃＤＮＡ全长３５１２ｂｐ,仅含一个３３４８ｂｐ的阅读框架,编码一人含有１１１６个氨基酸的蛋白（Ｐ２）。与基因库中已知基因序列比较,发现它与日本ＲＤＶＨ株系相应片段的核苷酸和氨基酸同源率分别为９４．６％和９５．４％与轮状病毒ＶＰ２氨基酸序列有一定     

水稻矮缩病毒最外层外壳蛋白基因(S_2)cDNA克隆、序列分析及其在大肠杆菌中的表达

从水稻矮缩病毒（Ｒｉｃｅｄｗａｒｆｖｉｒｕｓ,ＲＤＶ）中国福建分离物中克隆分离了最外层外壳蛋白基因（Ｓ２）全长ｃＤＮＡ,并对其进行了序列分析,结果表明ＲＤＶＳ２ｃＤＮＡ全长３５１２ｂｐ,仅含一个３３４８ｂｐ的阅读框架,编码一个含有１１１６个氨基酸的蛋白（Ｐ２）。与基因库中已知基因序列比较,发现它与日本ＲＤＶＨ株系相应片段的核苷酸和氨基酸同源率分别为９４６％和９５４％,与轮状病毒ＶＰ２氨基酸序列有一定的同源性。Ｓ２核苷酸序列二级结构预测结果表明,５’端５０个核苷酸的二级结构为一个发夹结构和一个茎环结构。Ｐ２有４个富含亮氨酸的区域,位于Ｎ端亲水区域的１０个氨基酸（ＡＡ６９～７８）残基形成一个α螺旋,这些特点均与轮状病毒ＶＰ２的结构特征相似。ＳＤＳＰＡＧＥ和Ｗｅｓｔｅｒｎ印迹分析表明在大肠杆菌中分段高效表达了Ｓ２编码蛋白的Ｎ端和Ｃ端。     

雪松聚球藻金属硫蛋白的纯化及其性质的研究

在雪松聚球藻的培养基中逐渐增加氯化镉的浓度以诱导藻细胞内金属硫蛋白的合成,经Ｓｅｐｈａｄｅｘ Ｇ－５０,ＤＥＡＥ－ｃｅｌｌｕｌｏｓｅ和Ｓｅｐｈａｄｅｘ Ｇ－２５柱层析,获得的ＭＴ没有亚型,经ＳＤＳ－ＰＡＧＥ分析是高度均一的。每个蛋白分子约含５个Ｃｄ原子,１０个巯基,分子量约为７．６ＫＤ,等电位ｐＨ４．５左右,半胱氨酸含量约占总氨基酸量的１５．５％,还含有少量的芳香族氨基酸,ＭＴ的最大紫外吸收在２５     

SAPGTP和PG为接头的5'IL6-TNFα衍生物融合蛋白

通过计算机模拟比较十种理论上柔性较好的接头在 ５′ Ｉ Ｌ６ Ｔ Ｎ ＦΔ融合蛋白中对 Ｉ Ｌ ６ 和 Ｔ Ｎ ＦΔ空间结构的影响情况,从中选择了 Ｓ Ａ Ｐ Ｇ Ｔ Ｐ接头．以 Ｓ Ａ Ｐ Ｇ Ｔ Ｐ 作为接头的 ５′ Ｉ Ｌ６ Ｓ Ａ Ｐ Ｇ Ｔ Ｐ Ｔ Ｎ ＦΔ和以 Ｐ Ｇ 为接头的５′ Ｉ Ｌ６ Ｐ Ｇ Ｔ Ｎ ＦΔ空间结构预测结果相似． Ｄ Ｎ Ａ 序列分析两种蛋白的接头序列均与设计的一致．５′ Ｉ Ｌ６ Ｓ Ａ Ｐ Ｇ Ｔ Ｐ Ｔ Ｎ ＦΔ和 ５′ Ｉ Ｌ６ Ｐ Ｇ Ｔ Ｎ ＦΔ蛋白的大肠杆菌表达产物经初步分离、纯化及鉴定后,生物学活性及对高表达 Ｉ Ｌ ６ 受体肿瘤细胞的杀伤作用比较结果显示：在 Ｌ９２９细胞上,前者的生物学活性是后者的 ２７ 倍;在 Ｕ９３７ 细胞上,前者对肿瘤细胞的抑制率是后者的１３ 倍．它们对高表达 Ｉ Ｌ ６ 受体的 Ｕ９３７ 细胞杀伤作用分别是同样突变位点的人 Ｔ Ｎ Ｆα衍生物的３７ 和 ２９ 倍．实验表明, Ｓ Ａ Ｐ Ｇ Ｔ Ｐ作为接头构建的 ５′ Ｉ Ｌ６ Ｓ Ａ Ｐ Ｇ Ｔ Ｐ Ｔ Ｎ ＦΔ融合蛋白优于以 Ｐ Ｇ 作为接头构建的 ５′ Ｉ Ｌ６ Ｐ Ｇ Ｔ Ｎ ＦΔ融合蛋白．     

PSP94-TNFαD11a融合基因在NIH3T3细胞中的表达及其产物活性分析

 为了分析 PSP94- TNFαD1 1 a融合基因的表达和表达产物的生物学活性 ,将含该融合基因的质粒 pc DNA- PSP94- TNFα D1 1 a转染 NIH3T3细胞 ,72 h后收集细胞培养上清 ,并提取细胞总RNA,经 RT- PCR,得到与目的基因长度相符合的 c DNA片段 ;以 PSP94c DNA为探针 ,对 RT-PCR产物进行 Southern印迹分析 .结果表明 :转染 PSP94- TNFαD1 1 a融合基因的 NIH3T3细胞 ,其 RT- PCR产物杂交信号为阳性 .细胞培养上清用 TNF抗体行 Western印迹和 ELISA分析 ,检测结果为阳性 .生物学活性分析表明 ,细胞培养上清不仅具有 PSP94抑制人前列腺癌细胞 PC- 3生长的活性 ,而且显示出 TNFα对 L92 9细胞的细胞毒作用 .以上结果表明 ,pc DNA- PSP94- TNFαD1 1 a质粒能够正确表达目的基因 PSP94- TNFα D1 1 a,且表达的 PSP94- TNFαD1 1 a融合蛋白具有预期的双重生物学活性 .     

Crystal Structure of Prostate Secretory Protein PSP94 Shows an Edge-to-Edge Association of two Monomers to Form a Homodimer

Several recent genome-wide association studies have linked the human MSMB gene, encoding prostate secretory protein of 94 residues (PSP94), with prostate cancer susceptibility. PSP94 is one of the most abundant proteins from prostatic secretions and a primary constituent of human semen. PSP94 suppresses tumor growth and metastasis, and its expression gradually decreases during progression of the prostate cancer. It is a rapidly evolving protein with homologues present in several species with 10 conserved cysteine residues. PSP94 homologues show high-affinity binding with different proteins from the cysteine-rich secretory protein family, some of which have been shown to be ion channel blockers. Here, we report the crystal structure of human PSP94 at 2.3 Å resolution. The structure shows that the amino and the carboxyl ends of the polypeptide chain are held in close proximity facing each other. A strong hydrogen bond between these ends, which are located respectively on the first and the last β-strands, leads to formation of an almost straight edge in PSP94 structure. Crystal structure shows that these edges from two PSP94 monomers associate in antiparallel fashion, leading to formation of a dimer. Our studies further show that dimers dissociate into monomers at acidic pH, possibly through distortion of the straight edge. Further, based on several observations, we propose that PSP94 binds to cysteine-rich secretory proteins and immunoglobulin G through the same edge, which is involved in the formation of PSP94 dimeric interface.     

Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (I) immuno-dominant and immuno-recessive area

PSP94 is a potential biomarker for evaluating patients with prostate carcinoma. We have systematically studied the epitope structure of PSP94 by using a polyclonal antibody against human PSP94. Results of peptide mapping and ELISA tests of dose response to rabbit antiserum against human PSP94 protein showed that only the N-terminal peptides (N30 and M23) are immunoreactive while all the synthetic peptides (C28, C10) located closer to the C-terminus are completely devoid of antigenic activity with the polyclonal antibody. These results were confirmed by analysis of reciprocal competitive binding of PSP94 polyclonal antibody by the N-terminal peptides (N30 and M23) v. either recombinant GST-PSP94 fusion protein, purified recombinant PSP94, or natural PSP94 protein. To further delineate the antigenic activity of the N- and C-termini, we have also expressed N- and C-terminal half of the whole PSP94 (each 47 peptides) using the E. coli GST expression system. The recombinant N47/C47 peptides were released by thrombin cleavage from the GST fusion protein and characterized by Western blotting experiments. Dose response of the recombinant GST-PSP-N47 and -C47 peptides to PSP94 polyclonal antibody showed differential binding activities. Competitive binding of these recombinant N47/C47 proteins against the GST-PSP94 protein demonstrates that the polyclonal antibody has a higher affinity for the N47 peptide than the C47 peptide. Based on the immunological studies of both synthetic peptides and recombinant PSP94- N/C terminal proteins, we propose an epitope structure of human PSP94 with an immno-dominant N-terminus and an immuno-recessive C-terminus. J. Cell. Biochem. 65:172–185. © 1997 Wiley-Liss, Inc.     

Recombinant PSP94 (prostate secretory protein of 94 amino acids) demonstrates similar linear epitope structure as natural PSP94 protein

PSP94 has the potential to be a useful diagnostic marker and therapeutic agent in prostate cancer. Recently, different immunoassay systems for quantitative analysis of PSP94 in clinical samples have been developed, but the epitope structure of PSP94 protein has not been elucidated. In this study, we report an Escherichia coli expression system for recombinant GST-PSP94 fusion protein. GST-PSP94 contains antigenic determinants similar to natural PSP94 protein (determined both by Western blotting experiments and by ELISA) and can be used to study the structure of natural PSP94 antigen. Since GST-PSP94 was expressed in E. coli and purification involved a denaturing process, we propose that the epitope structure of PSP94 is linear and largely dependent on the primary amino acid sequence, rather than conformational structure. This hypothesis was supported by reciprocal competition in ELISA among natural, GST-PSP94 fusion protein, and purified recombinant PSP94 protein. The results demonstrate that the various forms of PSP94 can compete with each other in binding to rabbit PSP94 polyclonal antibody, although the natural PSP94 has a slightly higher affinity. When natural and recombinant PSP94 protein were denatured in vitro with urea and alkali, no effect on the binding to antibody was found. The epitope activity of natural PSP94 was also shown to be resistant to the treatment of detergent and reducing agent. The location of one of the linear epitopes recognized by the PSP94 antibody was determined to be in the N-terminus by using two synthetic peptides representing N- and C-terminal sequences. Competitive ELISA between the N-terminal peptide and PSP94 protein indicate that both natural and GST-PSP94 have similar immunoactive N-termini. © 1996 Wiley-Liss, Inc.     

人PSP94与TNFα衍生物联合治疗人前列腺癌的实验研究

构建了表达人 PSP94、TNFα衍生物 ( TNFα D1 1 a)及 PSP94与 TNFα D1 1 a( PSP94- TNFαD1 1 a)双功能蛋白真核表达质粒 pc DNA- TNFα D1 1 a、pc DNA- PSP94和 pc DNA- PSP94- TNFαD1 1 a,与 rh PSP94和 rh TNFα D1 1 a蛋白分别在人前列腺癌裸鼠移植瘤动物模型上进行了 PSP94与 TNFαD1 1 a联合治疗人前列腺癌的实验研究 .当动物肿瘤直径长至约 1 0 mm时 ,将以上 3种真核表达质粒分别以 50 μg/只的量给相应组动物的左右四头肌内注射一次 ,同时设 pc DNA3.0空载体对照组 ;rh PSP9450μg/kg、rh TNFαD1 1 a 1 0 0万单位 /kg、rh PSP94和 rh TNFαD1 1 a以同样剂量联合给药 ,肌肉注射 ,每 d一次 ,连续 1 0 d,同时设环磷酰胺阳性对照组和生理盐水阴性对照组 .基因治疗动物给药后第 1 5d处死 ,蛋白治疗组停药后第 2 d处死 ,观察疗效 ,计算抑瘤率 .结果显示 ,以上述方式给药 ,无论是基因治疗组还是重组蛋白组 ,给 PSP94的动物肿瘤虽然未见明显缩小 ,但肿瘤组织均出现不同程度的坏死和液化现象 ;给 TNFαD1 1 a的未见明显的抑瘤效果 ;PSP94-TNFαD1 1 a融合基因或 rh PSP94+ rh TNFαD1 1 a联合给药 ,不仅肿瘤有所缩小 ,而且也有不同程度的坏死和液化现象出现 .初步认为 :( 1 ) PSP94有一定的抗前列腺     

人PSP94的分泌表达及其表达产物抗前列腺癌作用

将编码人 94个氨基酸的前列腺分泌蛋白 ( PSP94) c DNA与酵母整合载体 p PICZαA重组 ,构建的重组质粒线性化后转染酵母细胞 GS1 1 5,获得了 PSP94在酵母细胞中遗传性稳定表达酵母工程细胞 .诱导后的培养物中 ,rh PSP94表达量约为 0 .9mg/L,分子量约 1 6.5k D.培养上清经离子交换层析纯化后 ,目的蛋白的纯度为 92 % .体外在人前列腺癌细胞上活性分析表明 ,rh PSP94以1 0 0μg/L ,对该细胞的抑制率 2 0 .4% ;单纯新型 TNF,以 1 0 3 U/ml,抑制率 2 9.8% ;rh PSP94和新型 TNF以上述同样剂量联合应用 ,抑制率为 86.3% .提示 PSP94在体外对抗前列腺癌细胞有杀伤作用 ,但不明显 ;PSP94与新型 TNF联合应用 ,可使抑制率明显提高 ,可能 PSP94与新型 TNF有协同抗前列腺癌的作用 .     

Analysis of epitope structure of PSP94 (prostate secretory protein of 94 amino acids): (II) epitope mapping by monoclonal antibodies

PSP94 has shown potential to be a serum biomarker for evaluating prostate cancer. Studies of the epitope structure is crucial for this endeavour. In this article, we have used 15 different monoclonal antibodies (MAb) to analyse the epitope structure of PSP94 and to compare with the results obtained from our previous work using polyclonal antibody and recombinant PSP94. Firstly, we determined the relative activities of the 15 MAb population by direct and competitive ELISA. The two predominant MAbs (MAb PSP-6 and -19) in 15 MAbs were selected for further studies of the epitope structure. By comparing the binding activities of recombinant GST-PSP94 and natural PSP94 with MAbs, and by comparing their affinity with MAbs in an in vitro denaturing experiment, PSP94 was shown to have a similar, prevalently linear epitope structure as we demonstrated by polyclonal antibody. Using recombinant GST fusion protein with PSP94 and with each half of the N- and C-terminal 47 amino acids (GST-PSP-N47/C47) in E. coli cells, the different epitopes recognized by 15 monoclonal antibodies were delineated and the polar distribution of the epitope structure of PSP94 was characterized. Results of direct ELISA of recombinant N47 and C47 and their competitive binding against natural PSP94 (competitive ELISA) showed that the N- and C-termini represent the immuno-dominant and immuno-recessive area separately. A majority of the monoclonal antibodies (12/15) showed preferential binding of the N-terminal sequence of the PSP94 protein. Using GST-PSP-N47 as a standard protein, an epitope map of the 15 monoclonal antibodies was obtained. The results of this study will help to define the clinical utility of PSP94. J. Cell. Biochem. 65:186–197. © 1997 Wiley-Liss, Inc.     

Mouse PSP94 expression is prostate tissue-specific as demonstrated by a comparison of multiple antibodies against recombinant proteins

Prostate tissue-specific gene expression is crucial for driving potentially therapeutic genes to target specifically to the prostate. Prostate secretory protein of 94 amino acids (PSP94), also known as beta-MSP (microseminoprotein), is one of the three most abundant secretory proteins of the prostate gland, and is generally considered to be prostate tissue-specific. We have previously demonstrated that the expression of the rat PSP94 gene is strictly prostate tissue-specific by an antibody against a recombinant rat PSP94. In order to study prostate targeting utilizing the PSP94 gene in a mouse pre-clinical experimental model, we need to establish antibodies against mouse PSP94 to confirm if it is prostate tissue-specific as well. In this study, firstly we raised a polyclonal antibody against a recombinant glutathione-S-transferase- (GST-) mouse mature form of PSP94. However, it showed very poor immunoreactivity against prostate tissue PSP94 as tested in Western blotting experiments. Neither antibodies against rat PSP94 nor mouse PSP94 showed significant cross-reactivity. Thus a second antibody was established against a recombinant mouse mature PSP94 containing N-terminal polyhistidines, and stronger immunoreactivity against mouse prostate tissue PSP94 was identified in Western blotting experiments. Both of these antibodies showed immunohistochemical reactivity, while the latter showed stronger reactivity in IHC when tested with different fixatives. By studying tissue distribution, we demonstrated that, as with rat PSP94, mouse PSP94 is strictly prostate tissue-specific in experiments of both Western blotting and immunohistochemistry (IHC). This conclusion was also derived from a comparison among antibodies against human, rat, and mouse PSP94, showing very different immunoreactivities in Western blotting and IHC. Finally, a competitive assay between different species was performed. We demonstrated that antibodies against PSP94 from different species (human, primate, rodents) have poor cross-reactivities. These observations also indicate that the PSP94 gene is a rapidly evolving gene in all species. Results from this study have led to the possibility of utilizing PSP94 as a targeting agent specifically to the prostate in a mouse experimental model.     

94个氨基酸的前列腺分泌蛋白与TNFα衍生物的协同抗肿瘤作用(英文)

体外研究显示,重组PSP94与重组TNFα衍生物11a(rhTNFαDlla)有协同抗前列腺癌的作用。将编码这两种蛋白的基因与真核表达载体pcDNA30重组,构建成pcDNAPSP94TNFαDlla真核表达质粒,两基因中间通过一个编码6个氨基酸的人工接头连接。在体外,对pcDNAPSP94TNFαDlla质粒表达PSP94TNFαDlla蛋白的生物学活性鉴定表明,该蛋白即具有PSP94抑制前列腺癌细胞生长的活性,又具有TNFαDlla对L929细胞的细胞毒作用。肌肉注射该质粒DNA,注射后第9天血液中可检测到目的蛋白的表达,目的蛋白浓度的高峰期约在注射后第14天,第25天仍可检测到目的蛋白的表达。该质粒DNA以50μg只的量给人前列腺癌裸鼠模型骨四头肌内注射,同时设pcDNAPSP94、pcDNATNFαDlla、pcDNA30空载体和生理盐水对照组。注射后第20天处死动物,抑瘤率分别为:pcDNAPSP94TNFαDlla组24%,pcDNAPSP94组19%,pcDNATNFαDlla组瘤体大小与生理盐水组无明显差异。以同样方法给药,pcDNAPSP94TNFαDlla质粒DNA对小鼠Lweis肺癌的抑制率31%,是pcDNAPSP94组抑瘤率的22倍,是pcDNATNFαDlla组抑瘤率的21倍。提示,PSP94与TNF具有协同抗肿瘤的作用 。